Abstract: Described is a method for promoting regeneration of hematopoietic stem and progenitor cells in a subject in need thereof. The method comprises administering to the subject a composition comprising a Ca2+/calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2) inhibitor. The CaMKK2 inhibitor may be a small molecule inhibitor, such as 7H-benzimidazo(2,1-a)benz(de)isoquinoline-7-one-3-carboxylic acid (STO-609).
Abstract: The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Type:
Grant
Filed:
August 13, 2020
Date of Patent:
August 30, 2022
Assignee:
Incyte Corporation
Inventors:
Qinda Ye, Jingwei Li, Ken Mukai, Brandon Smith, Liangxing Wu, Wenqing Yao, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
Abstract: The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.
Type:
Grant
Filed:
March 5, 2021
Date of Patent:
August 23, 2022
Assignee:
XWPHARMA LTD.
Inventors:
Jia-Ning Xiang, Xuesong Xu, Yi Feng, Wai-Si Eng
Abstract: A Ruthenium complex containing alkynyl group, a method of synthesizing the Ruthenium complex containing alkynyl group and a use thereof are provided. The Ruthenium complex has a chemical formula of Ru(L)2(DPPZ?). DPPZ? is a main ligand having structural formula of R is any one selected from the group consisting of H, substituted or unsubstituted phenyl, R1NH2, R1OH, and SiMe3; R1 is C1-C5 chain alkyl group; L is an auxiliary ligand with N as coordinating atom. Sonogashira coupling reaction is utilized to introduce alkynyl group into a DPPZ-type Ruthenium complex; the introduced alkynyl group is beneficial to promote the transmembrane absorption of drug molecules, increase the probability of drug entry into cells, and can also increase efficacy and reduce toxic and side effects of drugs. The Ruthenium complex provided has significant anti-tumor activity, especially anti-breast cancer activity, and can provide new ideas for designing anti-tumor drug molecules in the future.
Abstract: The present invention relates to crystalline forms of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethylamine (“COMPOUND I”) useful in the treatment of RAGE mediated diseases.
Abstract: Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.
Type:
Grant
Filed:
April 29, 2019
Date of Patent:
August 23, 2022
Assignee:
BEIGENE, LTD.
Inventors:
Yunhang Guo, Hai Xue, Zhiwei Wang, Hanzi Sun
Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d; R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.
Type:
Grant
Filed:
February 15, 2019
Date of Patent:
August 23, 2022
Assignee:
AstraZeneca AB
Inventors:
Scott Nathan Mlynarski, Tyler Grebe, Sameer Kawatkar, Maurice Raymond Verschoyle Finlay, Iain Simpson, Jianyan Wang, Steve Cook, Dedong Wu
Abstract: The disclosure provides Group 6 complexes, which, in some embodiments, are useful for catalyzing olefin metathesis reactions. In some embodiments, the compounds are compounds of the following formula: wherein: M is a Group 6 metal atom; X is an oxygen atom, ?N—R5, ?N—N(R5)(R5?) or ?N—O—R5, R5 and R5? independently being various substituents, such as aryl or heteroaryl, each optionally substituted; n is 0 or 1; Rz is a neutral ligand; R1 is hydrogen or an organic substituent; R2 is an aryl or heteroaryl group, each optionally substituted; R3 is an anionic ligand; and R4 is an anionic ligand, such as a pyrrolide, a pyrazolide, an imidazolide, an indolide, an azaindolide, or an indazolide, each optionally substituted.
Type:
Grant
Filed:
August 7, 2020
Date of Patent:
August 16, 2022
Inventors:
Florian Toth, Georg Frater, Levente Ondi
Abstract: Provided is a platinum complex having a structure represented by formula (I): wherein A1 to A3 each independently represent a 5-membered or 6-membered unsaturated ring, A3 is optionally formed between A1 and A2; X1, X2, and X3 each independently represent carbon or nitrogen; R1 represents hydrogen, substituted or unsubstituted C1-C6 alkyl, —CF2H, —CFH2, substituted or unsubstituted C6-C12 aryl or —CmF2m+1, m is an integer of 1 to 5; R2 and R3 each independently represent hydrogen, C1-C12 alkyl, substituted or unsubstituted C1-C6 alkoxyl, substituted or unsubstituted C6-C12 aryl, or —CnF2n+1, n is an integer of 0 to 3; p and q each independently represent an integer of 1 to 2; and when p or q is equal to 2, two R2's or R3's may join to form a C3-C8 aromatic or nitrogen-containing heteroaromatic ring.
Type:
Grant
Filed:
January 14, 2021
Date of Patent:
August 16, 2022
Assignees:
National Tsing Hua University, City of University of Hong Kong
Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
Type:
Grant
Filed:
December 29, 2020
Date of Patent:
August 16, 2022
Assignee:
Incyte Corporation
Inventors:
Liangxing Wu, Kaijiong Xiao, Wenqing Yao
Abstract: The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.
Abstract: Provided herein are compounds, compositions, and pharmaceutical compositions of Formula (I). Also provided herein are methods of using compounds of Formula (I) to treat proliferative diseases, ocular diseases, dermatological diseases, inflammatory diseases, autoimmune diseases, autoinflammatory diseases, and metabolic diseases. Also provided herein are methods of using the compounds of Formula (I) as therapeutics, e.g., in the treatment and/or prevention of diseases associated with growth factor activity or angiogenesis. In some embodiments, the disease being treated is a proliferative disease.
Abstract: New deuterated analogs of elagolix are provided. The novel deuterated elagolix analogs differ from the only previously disclosed deuterated elagolix analogs in structure based on the exclusion of deuterium at certain sites in the compounds and the inclusion of deuterium at other sites. Also provided are new formulations for deuterated elagolix compounds and methods of using such compounds and formulations in the modification of mammalian physiology and especially in the treatment and prevention of a number of diseases and disorders, including endometriosis-associated pain and uterine fibroid conditions.
Type:
Grant
Filed:
January 13, 2020
Date of Patent:
August 2, 2022
Assignee:
Lupin, Inc.
Inventors:
James Garegnani, Nicholas Hart, Richard Holl
Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
Type:
Grant
Filed:
May 16, 2018
Date of Patent:
August 2, 2022
Assignee:
The University of Sheffield
Inventors:
Gareth Richards, Timothy M. Skerry, Joseph P. A. Harrity, Jean-Olivier Zirimwabagabo, Matthew J. Tozer, Karl Richard Gibson, Roderick Alan Porter, Paul Matthew Blaney, Paul Alan Glossop
Abstract: Compounds and compositions for use as starting materials or intermediate materials in the preparation of opioids including, e.g., oxycodone base and/or an oxycodone salt; processes for preparing these compounds and compositions; uses of these compounds and compositions in the preparation of APIs and pharmaceutical dosage forms; and uses of said APIs and pharmaceutical dosage forms in the treatment of medical conditions.
Type:
Grant
Filed:
September 8, 2020
Date of Patent:
July 19, 2022
Assignee:
RHODES TECHNOLOGIES
Inventors:
Stuart James Gebbie, Joshua R. Giguere, Keith Mccarthy, Lonn S. Rider
Abstract: A method is described for production of a high purity compound of the formula (I) in crystalline form of the modification A. In this, starting from high purity gadobutrol, the gadolinium is removed by decomplexation with oxalic acid, and then with a calcium salt the calcium complex is produced in high purity. During the crystallization, a water equivalent of 9-11 weight % is set. The crystalline form of the modification A of the compound of the formula (I) is used in the production of Gadovist.
Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.
Type:
Grant
Filed:
June 13, 2017
Date of Patent:
July 5, 2022
Assignees:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS SUD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUE